Baroreflex activation therapy: A new treatment option for heart failure with reduced ejection fraction

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 12, 2014, Pages 1465-1469

  Halbach, Marcel ^a   Hickethier, Tilman ^a,b   Madershahian, Navid ^a   Müller Ehmsen, Jochen ^a,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

Author keywords

Baroreceptor; Baroreflex activation therapy; Heart failure; Interventional treatment; Review

Indexed keywords

NORADRENALIN;

BAROREFLEX ACTIVATION THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART STIMULATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MUSCLE SYMPATHETIC NERVE ACTIVITY; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRESSORECEPTOR REFLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; SURVIVAL; ANIMAL; BLOOD PRESSURE; CAROTID SINUS; HEART LEFT VENTRICLE FUNCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSORECEPTOR;

ANIMALS; BAROREFLEX; BLOOD PRESSURE; CAROTID SINUS; HEART FAILURE; HUMANS; PRESSORECEPTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84912088784     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.979790     Document Type: Review

References (23)

1. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095
3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163
4. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677
5. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803
6. Sabbah HN, Gupta RC, Imai M, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 2011;4:65
7. Creager MA. Baroreceptor reflex function in congestive heart failure. Am J Cardiol 1992;69:10G
8. Rocca HP, Esler MD, Jennings GL, et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136
9. Bristow MR. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011;109:1176
10. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55:619
11. Sabbah HN. Baroreflex activation for the treatment of heart failure. Curr Cardiol Rep 2012;14:326
12. Zucker IH, Hackley JF, Cornish KG, et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007;50:904
13. Burgoyne S, Georgakopoulos D, Belenkie I, et al. Systemic vascular effects of acute electrical baroreflex stimulation. Am J Physiol Heart Circ Physiol 2014;307:H236
14. Braunwald E, Epstein SE, Glick G, et al. Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves. N Engl J Med 1967;277:1278
15. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;58:765
16. Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012;6:270
17. CVRx barostim hypertension pivotal trial. Available from: http://clinicaltrials.gov/show/NCT01679132
18. Halbach M, Hickethier T, Madershahian N, et al. Baroreflex activation therapy in resistant hypertension - acute on/off effects and chronic blood pressure reduction [abstract]. Clin Res Cardiol 2014;103(S1):1
19. Bisognano JD, Kaufman CL, Bach DS, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011;57:1787
20. Georgakopoulos D, Little WC, Abraham WT, et al. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail 2011;17:167
21. Gronda E, Seravalle G, Brambilla G, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014;16:977
22. Barostim Neo System in the treatment of heart failurea. Available from: http://clinicaltrials.gov/show/NCT01471860
23. Halbach M, Madershahian N, Brandt M-C, et al. Baroreflex activation therapy significantly lowers NTproBNP in patients with symptomatic heart failure [abstract]. Circulation 2012;126(21 Suppl):A15273